Hepatitis C prevalence among people who inject drugs in Hungary

The Lancet Infectious Diseases

Volumn 15, Issue 11, 2015, Pages 1261-1262

  Gyarmathy, V Anna ^a,b   Sárosi, Péter ^c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c Hungarian Civil Liberties Union   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE DERIVATIVE; CANNABIS; DESIGNER DRUG; DIAMORPHINE;

EPIDEMIC; HARM REDUCTION; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; HUNGARY; INTRAVENOUS DRUG ABUSE; LETTER; MATHEMATICAL MODEL; MISCELLANEOUS NAMED GROUPS; PEOPLE WHO INJECT DRUG; PREVALENCE; PRIORITY JOURNAL; COMPLICATION; SUBSTANCE ABUSE;

HEPATITIS C; HUMANS; HUNGARY; PREVALENCE; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84945251544     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)00358-8     Document Type: Letter

References (5)

1. National HIV and HCV prevalence related to intravenous drug use in 2014. Epinfo 2015, 22:189-194. National Centre for Epidemiology.
2. New psychoactive substances in Europe. An update from the EU Early Warning System 2015, European Monitoring Centre for Drugs and Drug Addiction, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, Portugal.
3. Sarafis P, Tsounis A Debt burden of Greece and HIV among injecting drug users. Lancet Infect Dis 2014, 14:180-181.
4. Technical Guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users, 2012 revision 2012, WHO, UNODCUNODC, UNAIDSUNAIDS, World Health Organization, Geneva.
5. Vickerman P, Hickman M The effect of epidemiological setting on the impact of harm reduction targeting injecting drug users. Harm reduction: evidence, impacts and challenges-EMCDDA scientific monograph 2010, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, Portugal. T. Rhodes (Ed.).